Male sex adversely impacts survival and myeloid malignancy risk in MGUS: a real-world population-based study
Eve Roman, Timothy Bagguley, S. Crouch, Alexandra Smith et autres
0 citationsHaematologica
Ruth de Tute
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
86Publications signalées
3638Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
Multiple Myeloma Research and TreatmentsLymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia ResearchMonoclonal and Polyclonal Antibodies ResearchHER2/EGFR in Cancer Research
Publications récentes
Double hit ultra-high risk myeloma treated with isatuximab, bortezomib, lenalidomide, dexamethasone and cyclophosphamide (Isa-VRDc) induction and isa-VRD consolidation: Initial results of the UK myeloma research alliance (UKMRA) RADAR trial in newly diagnosed transplant eligible patients
Karthik Ramasamy, Kara‐Louise Royle, Robert Cicero, Ruth de Tute et autres
0 citationsBlood
Acquired Bruton's tyrosine kinase mutations in patients treated on the ibrutinib and rituximab, ibrutinib alone, and ibrutinib and venetoclax arms of the national multi-centre Phase III FLAIR study in previously untreated CLL patients
Charlotte Evans, Surita Dalal, Darren Newton, Jennifer Carter et autres
3 citationsBlood
MRD-guided ibrutinib plus venetoclax improves outcomes in CLL patients with TP53, ATM, or NOTCH1 aberrations compared to ibrutinib and FCR: Results from the Phase III NCRI FLAIR trial
Surita Dalal, Jane Shingles, Sean Girvan, David Cairns et autres
1 citationBlood
Is IMWG frailty-score-adjusted dosing the right approach to improve toxicity and outcomes in FRAIL patients? Results from the UK-MRA FiTNEss trial in newly diagnosed myeloma patients ineligible for ASCT.
Charlotte Pawlyn, Kara‐Louise Royle, Ethan R Senior, Dax Everritt et autres
0 citationsBlood
Optimising MRD-guided treatment: UMRD4 as a half-way treatment timepoint for ibrutinib-venetoclax substantially delays MRD relapse after end of treatment in both IGHV-mutated and IGHV-unmutated CLL.
Andy C. Rawstron, David Cairns, Nichola Webster, Surita Dalal et autres
2 citationsBlood
Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial
David Lewis, Lexy Sorrell, D. Wright, Annika Pasanen et autres
22 citationsThe Lancet
Excised DNA circles from V(D)J recombination promote relapsed leukaemia
James N. Scott, Dylan Casey, Xiaoling Wang, Andrew Gillen et autres
3 citationsNature
47 | IBRUTINIB AND RITUXIMAB IS SUPERIOR TO IMMUNOCHEMOTHERAPY IN PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA DESPITE LOWER RATES OF MRD NEGATIVITY
David Lewis, Christopher Burton, Lexy Sorrell, Mats Jerkeman et autres
0 citationsHematological Oncology
Doubling in median survival in patients diagnosed with multiple myeloma 2005-2019; a real-world study from the UK’s Haematological Malignancy Research Network
Alexandra Smith, Timothy Bagguley, Eve Roman, Simon Crouch et autres
0 citationsHaematologica
Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial
Gordon Cook, A. John Ashcroft, Ethan R Senior, Catherine Olivier et autres
10 citationsThe Lancet Haematology
OA-59 Proteasome Inhibitor-Augmented Salvage Autologous Stem Cell Transplantation for First Relapse Management in Relapsed Multiple Myeloma
Christopher Parrish, Alexandra Welsh, John Ashcroft, Catherine Olivier et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.